Tau pathology as a driver and drug target for clinical dementia in AD - kindly supported by TauRX
About This Webinar
Professor Claude Wischik, Professor of Psychiatric Geratology, University of Aberdeen and CEO of TauRx Pharmaceuticals Ltd, will explain the current understanding of tau pathology, its role in Alzheimer’s disease and why it is an important target for disease modifying therapeutic intervention.

The multiple late-stage clinical trial failures in approaches based on β-amyloid have led to increasing attention and interest in tau protein pathology as a potential drug target. TauRx’s main focus for some 30 years has been on the molecular mechanisms responsible for pathological protein aggregation in progressive neurodegenerative disorders, and the development of viable therapeutic approaches in this area of high unmet medical need.

This session has been kindly supported by TauRx Pharmaceuticals Ltd.

About TauRx

TauRx's mission is to discover, develop and commercialise innovative products for the diagnosis, treatment and cure of neurodegenerative diseases caused through protein aggregation.

Contact: Rebecca Anderson: r.andersen@taurx.com



Twitter: @taurx

LinkedIn: https://www.linkedin.com/company/taurx-therapeutics/

YouTube: https://www.youtube.com/user/TauRxTherapeutics
  • 15.00-15.10 | Welcome and introduction to day | Professor Ramin Niforooshan and Professor Aimee Spector
  • 15.10-15.40 | Research Round-Up -Professor Clive Holmes
  • 15.40-16.10 | Medico-legal issues deprivation of liberty safeguards - Ben Troke
  • 16.25-16.55 | Drug and alcohol misuse in older people - Dr Tony Rao
  • 16.55-17.15 | Tau pathology as a driver and drug target for clinical dementia in AD - kindly supported by TauRX
  • 17.15-.17.20 | Break
  • 17.20-17.50 | Head Injury and Dementia - Professor David Sharp
  • 17.50-18.20 | Management of dementia services - Irene Lewsey
  • 18.20-18.30 | Sum up and close of conference
Professor Claude Wischik
Claude Wischik is Professor of Psychiatric Geratology at University of Aberdeen and Chairman/CEO of TauRx Pharmaceuticals and Genting TauRx Diagnostics (GTD). He was born in France, grew up in Australia and studied Medicine in Adelaide, Australia.

He did his PhD at the MRC Laboratory of Molecular Biology in Cambridge and completed specialist training in Psychiatry in Cambridge. He was appointed to his current position as Professor of Old Age Psychiatry at the University of Aberdeen in 1995.

In 2002, he co-founded TauRx Pharmaceuticals as a Singapore-incorporated company with the aim of discovering novel approaches to the treatment and diagnosis of Alzheimer’s disease and related disorders based on his discovery of a short fragment of Tau as the fundamental building block of the Alzheimer neurofibrillary tangle.

He has authored 150 scientific papers in the field of AD and has over 900 granted patents and additional pending applications covering the work of the team supporting the first tau-based treatment for AD and related neurodegenerative disorders.
This webinar will show you…
  • 1614524504-6d7303bb94c81211
    Biodesign® Hernia Graft
    The Biodesign® Hernia Graft is intended for implantation to reinforce soft tissues where weakness exists during ventral hernia repair.
  • 1614524505-9cda2ae63548f730
    Biodesign® Hiatal Hernia Graft
    The Biodesign® Hiatal Hernia Graft is used for implantation to reinforce soft tissues where weakness exists, during hiatal hernia repair.
  • 1614524506-5f4d7f2ac8c7747f
    Biodesign® Rectopexy Graft
    The Biodesign® Rectopexy Graft is intended to support/reinforce soft tissue in surgical procedures for open and laparoscopic repair of rectal prolapse/rectal intussusception.